Moderna, Natera, and AbbVie are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that use biotechnology to develop medicines, therapies, diagnostics, or other biological products. For investors, they can offer substantial growth potential, but their value may be especially sensitive to clinical-trial results, regulatory decisions, and funding needs. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
Moderna (MRNA)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Shares of NASDAQ:MRNA traded up $25.10 during midday trading on Friday, reaching $266.56. The company's stock had a trading volume of 9,671,213 shares, compared to its average volume of 12,617,172. The firm has a market cap of $106.42 billion, a price-to-earnings ratio of -33.42 and a beta of 1.16. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. Moderna has a 1 year low of $22.28 and a 1 year high of $265.62. The business has a 50 day moving average price of $189.62 and a 200 day moving average price of $90.46.
Read Our Latest Research Report on MRNA
Natera (NTRA)
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
NASDAQ:NTRA traded down $47.46 during mid-day trading on Friday, reaching $316.30. The company's stock had a trading volume of 2,578,779 shares, compared to its average volume of 1,441,692. The company's fifty day simple moving average is $380.81 and its two-hundred day simple moving average is $269.30. Natera has a twelve month low of $181.00 and a twelve month high of $437.41. The stock has a market cap of $45.59 billion, a P/E ratio of -233.37 and a beta of 1.55.
Read Our Latest Research Report on NTRA
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
AbbVie stock traded up $1.84 during midday trading on Friday, reaching $290.08. The stock had a trading volume of 1,097,815 shares, compared to its average volume of 6,329,698. The stock's 50-day simple moving average is $271.31 and its 200 day simple moving average is $238.65. AbbVie has a twelve month low of $190.75 and a twelve month high of $302.93. The stock has a market capitalization of $512.76 billion, a PE ratio of 49.96, a price-to-earnings-growth ratio of 1.34 and a beta of 0.20.
Read Our Latest Research Report on ABBV
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
